A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis
| Status: | Completed |
|---|---|
| Conditions: | Arthritis, Rheumatoid Arthritis |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 2/8/2019 |
| Start Date: | November 2005 |
| End Date: | November 2007 |
A Phase 1b/2 Multiple-Dose Safety Study and Pharmacokinetic/ Pharmacodynamic Study of LY2189102 in Patients With Rheumatoid Arthritis
The purpose of this study is to examine the safety and efficacy of this antibody in
participants with rheumatoid arthritis.
Part A of the study is an initial dose escalation phase
Part B of the study is a randomized allocation of the entire dosing group to parallel
treatment assignments
participants with rheumatoid arthritis.
Part A of the study is an initial dose escalation phase
Part B of the study is a randomized allocation of the entire dosing group to parallel
treatment assignments
Inclusion Criteria:
- diagnosis of rheumatoid arthritis
- regular use of methotrexate
- active rheumatoid arthritis
Exclusion Criteria:
- Juvenile Rheumatoid Arthritis
- evidence of tuberculosis
- women who are pregnant or become pregnant during study, or are breast-feeding
We found this trial at
11
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials